4956-63-2

Usage

InChI:InChI=1/C14H23NO2/c1-3-5-9-16-13-8-7-12(15)11-14(13)17-10-6-4-2/h7-8,11H,3-6,9-10,15H2,1-2H3

Upstream product

• 4956-77-8 3,4-di(butyloxy)nitrobenzene 
• 142-71-2 copper diacetate 
• 120-80-9 benzene-1,2-diol 
• 20367-35-5 1,2-dibutoxybenzene 

Downstream Products

• 98771-85-8 2-(3,4-Dibutoxy-phenylamino)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 101270-47-7 acetic acid-(4,5-dibutoxy-2-nitro-anilide) 
• 98772-35-1 2-(3,4-Dibutoxy-phenylamino)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and QCM gas-sensing properties of 3,4-dialkoxyphenyl tosylamino-substituted phthalocyanines

Octa-substituted metallophthalocyanines [M = Ni(II), Zn(II), Co(II), and Cu(II)] carrying 3,4-dialkoxyphenyl tosylamino groups at the peripheral positions have been synthesized from 1,2-dicyano-4,5-bis[(3,4-dialkoxyphenyl-tosylamino)methyl]benzene in the

A new class of discotic mesogens derived from tris(N-salicylideneaniline)s existing in C3h and Cs keto-enamine forms

(Chemical Equation Presented) Two series of a unique class of columnar liquid crystals derived from tris(N-salicylideneaniline)s [TSANs] in which the proton and the electron interact with each other through the H-bonding environment are reported. The synt

Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

This invention provides compounds having the structure: wherein X=CH, C(CH3) or N; each of R1, R2, R3, R4 and R5 is independently H, C1-C10 straight chained or branched alkyl, C2-C10 straight chained or branched alkenyl, C2-C10 straight chained or branched alkynyl, C3-C10 cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, —CN, —C(═Z)R6, —C(═Z)OR6, —C(═Z)N(R6)2, —N(R6)—C(═Z)R6, —N(R6)—C(═Z)N(R6)2, —OC(═Z)R6, —C(═Z)OR6—OR6 or —SR6; wherein Z is O or S; and wherein R6 is C1-C10 straight chained or branched alkyl, aryl, (CH2)nQ, C2-C10 alkenyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, wherein Q is OR7, SR7, N(R7)2 or aryl, wherein R7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R2 and R3 and the carbons to which they are attached form a fused aryl, heteroaryl, C5-C10 cyclic alkyl or heterocyclic alkyl ring; or wherein R3 and R4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from Ra, where Ra is 1) hydroxy, 2) C1-C10 alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF3, or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from Rb, where Rb is 1) a group selected from Ra, 2) C1-C7 alkyl, 3) C2-C7 alkenyl, 4) C2-C7 alkynyl or 5) cyclic C1-C10 alkyl, and each aryl is optionally substituted with R1. This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.

Compounds for the treatment of pain

This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.